APO Research
Talk to an analyst

APO RESEARCH · REPORT

Specific COX-2 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Specific COX-2 Inhibitors Market Outlook and Growth Opportunities 2026

27 December 2025207 pages

Choose your research edition.

Industry ResearchSpecific COX-2 Inhibitors Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Specific COX-2 Inhibitors Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Specific COX-2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Specific COX-2 Inhibitors Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Specific COX-2 Inhibitors Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Specific COX-2 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Specific COX-2 Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Specific COX-2 Inhibitors market include Actavis, Eskayef Pharmaceuticals, Mylan Pharmaceutical, Neopharmed Gentili, Organon Pharma, Pfizer, Teva, Zentiva and Zydus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Specific COX-2 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Specific COX-2 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Specific COX-2 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Specific COX-2 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Specific COX-2 Inhibitors Segment by Company

Actavis

Eskayef Pharmaceuticals

Mylan Pharmaceutical

Neopharmed Gentili

Organon Pharma

Pfizer

Teva

Zentiva

Zydus

Beijing Yabao Biological Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Jiangsu Chiatai Qingjiang Pharmaceutical

Qilu Pharmaceutical

Qingdao Baheal Medical

Shanxi Tongda Pharmaceutical

Sichuan Kelun Pharmaceutical

Specific COX-2 Inhibitors Segment by Type

Etoricoxib

Celecoxib

Imrecoxib

Other

Specific COX-2 Inhibitors Segment by Application

Osteoarthritis and Rheumatoid Arthritis

Relieve Acute Pain

Dysmenorrhea

Other

Specific COX-2 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Specific COX-2 Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Specific COX-2 Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Specific COX-2 Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Specific COX-2 Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Specific COX-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Specific COX-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Specific COX-2 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Specific COX-2 Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Specific COX-2 Inhibitors industry.

Chapter 3: Detailed analysis of Specific COX-2 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Specific COX-2 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Specific COX-2 Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Specific COX-2 Inhibitors Industry Trends Table 2. Specific COX-2 Inhibitors Industry Drivers Table 3. Specific COX-2 Inhibitors Industry Opportunities and Challenges Table 4. Specific COX-2 Inhibitors Industry Restraints Table 5. Global Specific COX-2 Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Specific COX-2 Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Specific COX-2 Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Specific COX-2 Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Specific COX-2 Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Specific COX-2 Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Specific COX-2 Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Specific COX-2 Inhibitors Company, Product Type & Application Table 13. Global Specific COX-2 Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Specific COX-2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Etoricoxib Table 18. Significant Companies of Celecoxib Table 19. Significant Companies of Imrecoxib Table 20. Significant Companies of Other Table 21. Global Specific COX-2 Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Specific COX-2 Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Specific COX-2 Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Specific COX-2 Inhibitors Sales Volume Share by Type (2021-2026) Table 25. Global Specific COX-2 Inhibitors Sales Volume Share by Type (2027-2032) Table 26. Global Specific COX-2 Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Specific COX-2 Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Specific COX-2 Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Specific COX-2 Inhibitors Sales Value Share by Type (2021-2026) Table 30. Global Specific COX-2 Inhibitors Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Osteoarthritis and Rheumatoid Arthritis Table 32. Significant Companies of Relieve Acute Pain Table 33. Significant Companies of Dysmenorrhea Table 34. Significant Companies of Other Table 35. Global Specific COX-2 Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Specific COX-2 Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Specific COX-2 Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Specific COX-2 Inhibitors Sales Volume Share by Application (2021-2026) Table 39. Global Specific COX-2 Inhibitors Sales Volume Share by Application (2027-2032) Table 40. Global Specific COX-2 Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Specific COX-2 Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Specific COX-2 Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Specific COX-2 Inhibitors Sales Value Share by Application (2021-2026) Table 44. Global Specific COX-2 Inhibitors Sales Value Share by Application (2027-2032) Table 45. Global Specific COX-2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Specific COX-2 Inhibitors Sales by Region (2021-2026) & (K Units) Table 47. Global Specific COX-2 Inhibitors Sales Market Share by Region (2021-2026) Table 48. Global Specific COX-2 Inhibitors Sales by Region (2027-2032) & (K Units) Table 49. Global Specific COX-2 Inhibitors Sales Market Share by Region (2027-2032) Table 50. Global Specific COX-2 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Specific COX-2 Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Specific COX-2 Inhibitors Sales Value Share by Region (2021-2026) Table 53. Global Specific COX-2 Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Specific COX-2 Inhibitors Sales Value Share by Region (2027-2032) Table 55. Global Specific COX-2 Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Specific COX-2 Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Specific COX-2 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Specific COX-2 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 60. Global Specific COX-2 Inhibitors Sales Market Share by Country (2021-2026) Table 61. Global Specific COX-2 Inhibitors Sales by Country (2027-2032) & (K Units) Table 62. Global Specific COX-2 Inhibitors Sales Market Share by Country (2027-2032) Table 63. Global Specific COX-2 Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Specific COX-2 Inhibitors Sales Value Market Share by Country (2021-2026) Table 65. Global Specific COX-2 Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Specific COX-2 Inhibitors Sales Value Market Share by Country (2027-2032) Table 67. Actavis Company Information Table 68. Actavis Business Overview Table 69. Actavis Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Actavis Specific COX-2 Inhibitors Product Portfolio Table 71. Actavis Recent Development Table 72. Eskayef Pharmaceuticals Company Information Table 73. Eskayef Pharmaceuticals Business Overview Table 74. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio Table 76. Eskayef Pharmaceuticals Recent Development Table 77. Mylan Pharmaceutical Company Information Table 78. Mylan Pharmaceutical Business Overview Table 79. Mylan Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 81. Mylan Pharmaceutical Recent Development Table 82. Neopharmed Gentili Company Information Table 83. Neopharmed Gentili Business Overview Table 84. Neopharmed Gentili Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio Table 86. Neopharmed Gentili Recent Development Table 87. Organon Pharma Company Information Table 88. Organon Pharma Business Overview Table 89. Organon Pharma Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Organon Pharma Specific COX-2 Inhibitors Product Portfolio Table 91. Organon Pharma Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Pfizer Specific COX-2 Inhibitors Product Portfolio Table 96. Pfizer Recent Development Table 97. Teva Company Information Table 98. Teva Business Overview Table 99. Teva Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Teva Specific COX-2 Inhibitors Product Portfolio Table 101. Teva Recent Development Table 102. Zentiva Company Information Table 103. Zentiva Business Overview Table 104. Zentiva Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Zentiva Specific COX-2 Inhibitors Product Portfolio Table 106. Zentiva Recent Development Table 107. Zydus Company Information Table 108. Zydus Business Overview Table 109. Zydus Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Zydus Specific COX-2 Inhibitors Product Portfolio Table 111. Zydus Recent Development Table 112. Beijing Yabao Biological Pharmaceutical Company Information Table 113. Beijing Yabao Biological Pharmaceutical Business Overview Table 114. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 116. Beijing Yabao Biological Pharmaceutical Recent Development Table 117. Jiangsu Hengrui Pharmaceuticals Company Information Table 118. Jiangsu Hengrui Pharmaceuticals Business Overview Table 119. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio Table 121. Jiangsu Hengrui Pharmaceuticals Recent Development Table 122. Jiangsu Chiatai Qingjiang Pharmaceutical Company Information Table 123. Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview Table 124. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 126. Jiangsu Chiatai Qingjiang Pharmaceutical Recent Development Table 127. Qilu Pharmaceutical Company Information Table 128. Qilu Pharmaceutical Business Overview Table 129. Qilu Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 131. Qilu Pharmaceutical Recent Development Table 132. Qingdao Baheal Medical Company Information Table 133. Qingdao Baheal Medical Business Overview Table 134. Qingdao Baheal Medical Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio Table 136. Qingdao Baheal Medical Recent Development Table 137. Shanxi Tongda Pharmaceutical Company Information Table 138. Shanxi Tongda Pharmaceutical Business Overview Table 139. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 141. Shanxi Tongda Pharmaceutical Recent Development Table 142. Sichuan Kelun Pharmaceutical Company Information Table 143. Sichuan Kelun Pharmaceutical Business Overview Table 144. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 146. Sichuan Kelun Pharmaceutical Recent Development Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Specific COX-2 Inhibitors Distributors List Table 150. Specific COX-2 Inhibitors Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Specific COX-2 Inhibitors Product Image Figure 2. Global Specific COX-2 Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Specific COX-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Specific COX-2 Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Specific COX-2 Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Specific COX-2 Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Etoricoxib Image Figure 10. Celecoxib Image Figure 11. Imrecoxib Image Figure 12. Other Image Figure 13. Global Specific COX-2 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Specific COX-2 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Specific COX-2 Inhibitors Sales Volume Share by Type (2021-2032) Figure 16. Global Specific COX-2 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Specific COX-2 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Specific COX-2 Inhibitors Sales Value Share by Type (2021-2032) Figure 19. Osteoarthritis and Rheumatoid Arthritis Image Figure 20. Relieve Acute Pain Image Figure 21. Dysmenorrhea Image Figure 22. Other Image Figure 23. Global Specific COX-2 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Specific COX-2 Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Specific COX-2 Inhibitors Sales Volume Share by Application (2021-2032) Figure 26. Global Specific COX-2 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Specific COX-2 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Specific COX-2 Inhibitors Sales Value Share by Application (2021-2032) Figure 29. Global Specific COX-2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Specific COX-2 Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Specific COX-2 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Specific COX-2 Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Specific COX-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 34. North America Specific COX-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Specific COX-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Specific COX-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Specific COX-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Specific COX-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Specific COX-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 40. South America Specific COX-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Specific COX-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Specific COX-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Specific COX-2 Inhibitors Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Specific COX-2 Inhibitors Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Etoricoxib
  • Celecoxib
  • Imrecoxib
  • Other
Applications
  • Osteoarthritis and Rheumatoid Arthritis
  • Relieve Acute Pain
  • Dysmenorrhea
  • Other
Companies covered
  • Actavis
  • Eskayef Pharmaceuticals
  • Mylan Pharmaceutical
  • Neopharmed Gentili
  • Organon Pharma
  • Pfizer
  • Teva
  • Zentiva
  • Zydus
  • Beijing Yabao Biological Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Jiangsu Chiatai Qingjiang Pharmaceutical
  • Qilu Pharmaceutical
  • Qingdao Baheal Medical
  • Shanxi Tongda Pharmaceutical
  • Sichuan Kelun Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Specific COX-2 Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Specific COX-2 Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Specific COX-2 Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Specific COX-2 Inhibitors Market Dynamics
  1. 2.1 Specific COX-2 Inhibitors Industry Trends
  2. 2.2 Specific COX-2 Inhibitors Industry Drivers
  3. 2.3 Specific COX-2 Inhibitors Industry Opportunities and Challenges
  4. 2.4 Specific COX-2 Inhibitors Industry Restraints
3 Specific COX-2 Inhibitors Market by Company
  1. 3.1 Global Specific COX-2 Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Specific COX-2 Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Specific COX-2 Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Specific COX-2 Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Specific COX-2 Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Specific COX-2 Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Specific COX-2 Inhibitors Company Product Type and Application
  8. 3.8 Global Specific COX-2 Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Specific COX-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Specific COX-2 Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Specific COX-2 Inhibitors Market by Type
  1. 4.1 Specific COX-2 Inhibitors Type Introduction
  2. 4.1.1 Etoricoxib
  3. 4.1.2 Celecoxib
  4. 4.1.3 Imrecoxib
  5. 4.1.4 Other
  6. 4.2 Global Specific COX-2 Inhibitors Sales Volume by Type
  7. 4.2.1 Global Specific COX-2 Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Specific COX-2 Inhibitors Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Specific COX-2 Inhibitors Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Specific COX-2 Inhibitors Sales Value by Type
  11. 4.3.1 Global Specific COX-2 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Specific COX-2 Inhibitors Sales Value by Type (2021-2032)
  13. 4.3.3 Global Specific COX-2 Inhibitors Sales Value Share by Type (2021-2032)
5 Specific COX-2 Inhibitors Market by Application
  1. 5.1 Specific COX-2 Inhibitors Application Introduction
  2. 5.1.1 Osteoarthritis and Rheumatoid Arthritis
  3. 5.1.2 Relieve Acute Pain
  4. 5.1.3 Dysmenorrhea
  5. 5.1.4 Other
  6. 5.2 Global Specific COX-2 Inhibitors Sales Volume by Application
  7. 5.2.1 Global Specific COX-2 Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Specific COX-2 Inhibitors Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Specific COX-2 Inhibitors Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Specific COX-2 Inhibitors Sales Value by Application
  11. 5.3.1 Global Specific COX-2 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Specific COX-2 Inhibitors Sales Value by Application (2021-2032)
  13. 5.3.3 Global Specific COX-2 Inhibitors Sales Value Share by Application (2021-2032)
6 Specific COX-2 Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Specific COX-2 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Specific COX-2 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Specific COX-2 Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Specific COX-2 Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Specific COX-2 Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Specific COX-2 Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Specific COX-2 Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Specific COX-2 Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Specific COX-2 Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Specific COX-2 Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Specific COX-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Specific COX-2 Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Specific COX-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Specific COX-2 Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Specific COX-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Specific COX-2 Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Specific COX-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Specific COX-2 Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Specific COX-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Specific COX-2 Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Specific COX-2 Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Specific COX-2 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Specific COX-2 Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Specific COX-2 Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Specific COX-2 Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Specific COX-2 Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Specific COX-2 Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Specific COX-2 Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Specific COX-2 Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Specific COX-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Specific COX-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Actavis
  2. 8.1.1 Actavis Company Information
  3. 8.1.2 Actavis Business Overview
  4. 8.1.3 Actavis Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Actavis Specific COX-2 Inhibitors Product Portfolio
  6. 8.1.5 Actavis Recent Developments
  7. 8.2 Eskayef Pharmaceuticals
  8. 8.2.1 Eskayef Pharmaceuticals Company Information
  9. 8.2.2 Eskayef Pharmaceuticals Business Overview
  10. 8.2.3 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
  12. 8.2.5 Eskayef Pharmaceuticals Recent Developments
  13. 8.3 Mylan Pharmaceutical
  14. 8.3.1 Mylan Pharmaceutical Company Information
  15. 8.3.2 Mylan Pharmaceutical Business Overview
  16. 8.3.3 Mylan Pharmaceutical Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  18. 8.3.5 Mylan Pharmaceutical Recent Developments
  19. 8.4 Neopharmed Gentili
  20. 8.4.1 Neopharmed Gentili Company Information
  21. 8.4.2 Neopharmed Gentili Business Overview
  22. 8.4.3 Neopharmed Gentili Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio
  24. 8.4.5 Neopharmed Gentili Recent Developments
  25. 8.5 Organon Pharma
  26. 8.5.1 Organon Pharma Company Information
  27. 8.5.2 Organon Pharma Business Overview
  28. 8.5.3 Organon Pharma Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Organon Pharma Specific COX-2 Inhibitors Product Portfolio
  30. 8.5.5 Organon Pharma Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Specific COX-2 Inhibitors Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Teva
  38. 8.7.1 Teva Company Information
  39. 8.7.2 Teva Business Overview
  40. 8.7.3 Teva Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Teva Specific COX-2 Inhibitors Product Portfolio
  42. 8.7.5 Teva Recent Developments
  43. 8.8 Zentiva
  44. 8.8.1 Zentiva Company Information
  45. 8.8.2 Zentiva Business Overview
  46. 8.8.3 Zentiva Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Zentiva Specific COX-2 Inhibitors Product Portfolio
  48. 8.8.5 Zentiva Recent Developments
  49. 8.9 Zydus
  50. 8.9.1 Zydus Company Information
  51. 8.9.2 Zydus Business Overview
  52. 8.9.3 Zydus Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Zydus Specific COX-2 Inhibitors Product Portfolio
  54. 8.9.5 Zydus Recent Developments
  55. 8.10 Beijing Yabao Biological Pharmaceutical
  56. 8.10.1 Beijing Yabao Biological Pharmaceutical Company Information
  57. 8.10.2 Beijing Yabao Biological Pharmaceutical Business Overview
  58. 8.10.3 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  60. 8.10.5 Beijing Yabao Biological Pharmaceutical Recent Developments
  61. 8.11 Jiangsu Hengrui Pharmaceuticals
  62. 8.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
  63. 8.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  64. 8.11.3 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
  66. 8.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  67. 8.12 Jiangsu Chiatai Qingjiang Pharmaceutical
  68. 8.12.1 Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
  69. 8.12.2 Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview
  70. 8.12.3 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  72. 8.12.5 Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments
  73. 8.13 Qilu Pharmaceutical
  74. 8.13.1 Qilu Pharmaceutical Company Information
  75. 8.13.2 Qilu Pharmaceutical Business Overview
  76. 8.13.3 Qilu Pharmaceutical Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  78. 8.13.5 Qilu Pharmaceutical Recent Developments
  79. 8.14 Qingdao Baheal Medical
  80. 8.14.1 Qingdao Baheal Medical Company Information
  81. 8.14.2 Qingdao Baheal Medical Business Overview
  82. 8.14.3 Qingdao Baheal Medical Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio
  84. 8.14.5 Qingdao Baheal Medical Recent Developments
  85. 8.15 Shanxi Tongda Pharmaceutical
  86. 8.15.1 Shanxi Tongda Pharmaceutical Company Information
  87. 8.15.2 Shanxi Tongda Pharmaceutical Business Overview
  88. 8.15.3 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  90. 8.15.5 Shanxi Tongda Pharmaceutical Recent Developments
  91. 8.16 Sichuan Kelun Pharmaceutical
  92. 8.16.1 Sichuan Kelun Pharmaceutical Company Information
  93. 8.16.2 Sichuan Kelun Pharmaceutical Business Overview
  94. 8.16.3 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  96. 8.16.5 Sichuan Kelun Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Specific COX-2 Inhibitors Value Chain Analysis
  2. 9.1.1 Specific COX-2 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Specific COX-2 Inhibitors Sales Mode & Process
  6. 9.2 Specific COX-2 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Specific COX-2 Inhibitors Distributors
  9. 9.2.3 Specific COX-2 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst